Aspen Neuroscience, Inc.

This week, our VP of Process and Analytical Development, Thorsten Gorba, presented at the Terrapinn Advanced Therapies Conference in Philadelphia. On Tuesday, Thorsten served on the panel discussion "Staying Agile and Embracing Technological Innovations to Optimize Cell Therapy Manufacturing." On Wednesday he presented “Manufacturing and Testing of Autologous iPSC-Derived Cell Therapies." Thank you?Terrapinn for hosting this event! #ParkinsonsDisease #CellTherapy #Autologous #RegenerativeMedicine

Aspen Neuroscience Chief Financial Officer?Kameel Farag will present company updates in a fireside chat today at?4:15 pm PT?at the UBS Global Healthcare Conference in?Rancho Palos Verdes, Calif., where he will detail?Aspen’s?latest developments and future strategic plans for treating neurodegenerative diseases, including Parkinson’s disease. The UBS Global Conference is designed to bring together a premier group of C-Suite executives and institutional investors. https://lnkd.in/gjtB-8G5 #ParkinsonsDisease #CellTherapy #iPSCs #RegenerativeMedicine

This week, Endpoints News Honored Aspen Neuroscience Co-Founder Dr. Jeanne Loring in “20 Women Breaking New Ground." Congratulations, Jeanne! “Research launched by Dr. Loring and continued by?Aspen?is making significant strides in the field of human pluripotent stem cells. It is not only groundbreaking but also holds immense promise for the future of regenerative medicine,” said Damien McDevitt, CEO. Read more here: https://lnkd.in/gUhxEDda #celltherapy

It’s Day 2 of the Alliance for Regenerative Medicine’s 2024 Cell & Gene Meeting on the Mesa. ? We're looking forward to our company presentation by Kim Raineri, Chief Technical Officer. Catch up on all the?news at Aspen today at 1:30 pm at the Frank Lloyd Wright Ballroom G. ? Check out the full lineup of speakers and presentations:?www.meetingonthemesa.com #CGMesa24 #Cellandgenetherapy

Today we announced our collaboration and license agreement with Cell X Technologies to advance our plans to automate the iPSC stage of our autologous manufacturing platform. "In order to treat greater numbers of patients with their own cells, Aspen is?developing a robust, scalable, and automated biomanufacturing system. We have worked with the Celligent platform and?believe that, combined with our bioinformatics and other enabling technologies, it?has the potential to successfully automate iPSC production," said Kim Raineri, Chief Technology Officer. Read more here: https://lnkd.in/eY4v2Trq #celltherapy #iPSC #parkinsonsdisease #autologous #innovation

The Aspen Neuroscience team is attending the Alliance for Regenerative Medicine’s 2024 Cell and Gene Meeting on the Mesa on the Mesa this week. Can't wait to dive into discussions, network with industry leaders, and explore the latest advancements in #cellandgenetherapy. ? ? Be sure to check out the Aspen Neuroscience’s Xiaokui Zhang, PhD, at the Science Slam: Neurological Diseases. This afternoon at 4:00 – see you there! #CGMesa24 https://lnkd.in/g5b7nvQH

This week, at the International Society for Stem Cell Research 2024 Copenhagen International Symposium, our co-founder and SVP, Research, Andrés Bratt-Leal, PhD, will deliver two presentations. Today, he will present an update on “Pre-Clinical Safety and Efficacy of Dopamine Neuron Progenitor Cells Derived from PD Donor-Induced Pluripotent Stem Cells.” And Friday, October 4, he will serve on a panel discussion on “PSC-Derived Drug Product, Cell Delivery, and Clinical Trials,” featuring esteemed leaders in the cell therapy industry. The ISSCR Symposium gathers world-renowned scientists and innovators at the forefront of stem cell therapies to share the latest updates on ongoing clinical trials, groundbreaking platforms, and technologies that will revolutionize the next generation of cell therapies for devastating and intractable diseases. If you are attending this meeting, please stop by the talks and hear the latest updates on what is going on in the autologous field! #iPSC #parkinson's #celltherapy #autologous #innovation

We are excited to announce that we’ve opened our 22,000 square foot expansion facility for GMP manufacturing of induced pluripotent stem cell (iPSC)-derived cell therapies. The new?facility is certified?by the Food and Drug Branch (FDB) of the California Department of Public Health. The Aspen team is currently producing patient-specific clinical drug product using in-house manufacturing and Quality Control (QC). "This new site will help accelerate the manufacture of patient-specific cell lines for our ASPIRO trial patients in California and across the U.S.," said Damien McDevitt, PhD, president and CEO of Aspen Neuroscience. Read more here: https://lnkd.in/g3g-VWYy #celltherapy

Our Chief Financial Officer, Kameel Farag, will present this week at three biotechnology investor conferences, where he will provide company updates detailing Aspen's latest developments and future strategic plans for treating neurodegenerative diseases, including Parkinson's disease. Please find details on each presentation in the link below! https://lnkd.in/gVCBGgba #parkinsonsdisease #celltherapy

The Aspen team is currently at the MDS International Congress of Parkinson's Disease and Movement Disorders, taking place in Philadelphia, where we will be presenting surgical safety data from our first cohort. If you are attending the MDS conference, please stop by booth 1003 and say hello! #celltherapy #parkinsonsdisease